-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
-
Summary
-
Adaptimmune Therapeutics PLC annual/quarterly Amortization of Intangible Assets history and growth rate from Q3 2015 to Q1 2022.
- Adaptimmune Therapeutics PLC Amortization of Intangible Assets for the quarter ending March 31, 2022 was $4.21M.
- Adaptimmune Therapeutics PLC annual Amortization of Intangible Assets for 2023 was $366K, a 54.8% decline from 2022.
- Adaptimmune Therapeutics PLC annual Amortization of Intangible Assets for 2022 was $809K, a 13.7% decline from 2021.
- Adaptimmune Therapeutics PLC annual Amortization of Intangible Assets for 2021 was $937K, a 3.1% decline from 2020.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)